{{Rsnum
|rsid=72552784
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Orientation=plus
|Orientation=plus
|Chromosome=7
|position=87516598
|Gene=ABCB1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=ABCB1
}}{{PharmGKB
|RSID=rs72552784
|Name_s=ABCB1: c.2995G>A, mRNA 3413G>A, p.Ala999Thr
|Gene_s=ABCB1
|Feature=
|Evidence=PubMed ID:12065748
|Annotation=Drug efflux and cell surface expression (by MRK-16 and C219 probes) of P-gp was not different between wild-type and variant forms (single mutants: N21D, F103L, S400N, A893S, A998T, and double mutants: 21D-S400N, N21D-A893S, and S400N-A893S) in an in vitro vaccinia virus-based transient expression system. Fluroescent substrates included calcein AM, bodipy-FL-forskolin, bodipy-FL-verapamil, bodipy-FL-vinblastine, bodipy-FL-prazosin, bisantrene, and bodipy-FL-paclitaxel. There was a slight increase in wild-type P-gp efflux of bodipy-FL-paclitaxel over mutants.
|Drugs=bisantrene; calcein; forskolin; prazosin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110366
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}